Emergent BioSolutions (EBS) Gains from Investment Securities (2014 - 2026)
Emergent BioSolutions (EBS) posted quarterly Gains from Investment Securities of -$8.4 million for Q1 2026, up 11.58% year-over-year from -$7.5 million in Q1 2025, and up 11.58% quarter-over-quarter from -$9.5 million in Q1 2025.
Emergent BioSolutions (EBS) Gains from Investment Securities (2014 - 2026) Analysis & Trends
Emergent BioSolutions' Gains from Investment Securities history runs 13 years deep, the most recent figure standing at -$8.4 million for Q1 2026.
- In Q1 2026, Gains from Investment Securities rose 11.58% year-over-year to -$8.4 million; the TTM figure through Mar 2026 stood at -$8.4 million (up 10.64% YoY), while the FY2024 annual figure was $600000.0, up 200.0% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at -$8.4 million, up from -$9.5 million in the prior quarter.
- The five-year high for Gains from Investment Securities was $1.3 million in Q2 2022, with the low at -$9.5 million in Q1 2025.
- The 5-year median for Gains from Investment Securities is $300000.0 (2023), against an average of -$1.6 million.
- Peak annual rise in Gains from Investment Securities reached 125.0% in 2023, while the deepest fall reached 283.33% in 2023.
- Emergent BioSolutions' Gains from Investment Securities stood at -$2.4 million in 2022, then soared by 125.0% to $600000.0 in 2023, then plunged by 83.33% to $100000.0 in 2024, then sank by 9600.0% to -$9.5 million in 2025, then grew by 11.58% to -$8.4 million in 2026.
- Business Quant data shows EBS's Gains from Investment Securities at -$8.4 million in Q1 2026, -$9.5 million in Q1 2025, and $100000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Emergent BioSolutions | 251.81 Mn | 110.91 Mn | 137.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -500,000.00 |
| Jun 30, 2026 | -500,000.00 |
| Mar 31, 2026 | -8.40 Mn |
| Mar 31, 2026 | -8.40 Mn |
| Mar 31, 2025 | -9.50 Mn |
| Mar 31, 2025 | -9.50 Mn |
| Jun 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Dec 31, 2023 | 600,000.00 |
| Dec 31, 2023 | 600,000.00 |
| Sep 30, 2023 | -1.10 Mn |
| Sep 30, 2023 | -1.10 Mn |
| Jun 30, 2023 | 400,000.00 |
| Jun 30, 2023 | 400,000.00 |
| Mar 31, 2023 | 300,000.00 |
| Mar 31, 2023 | 300,000.00 |
| Dec 31, 2022 | -2.40 Mn |
| Dec 31, 2022 | -2.40 Mn |
| Sep 30, 2022 | 600,000.00 |
| Sep 30, 2022 | 600,000.00 |